Oragenics (NYSE American: OGEN) announced that two patients have been enrolled and eight doses administered in its ongoing Phase IIa clinical trial evaluating ONP-002, its lead candidate for the treatment of mild traumatic brain injury (mTBI), or concussion. The trial is underway at Mackay Base Hospital in Queensland, Australia, with additional sites nearing activation, as the company advances a first-in-class intranasal neurosteroid designed to target the underlying biological effects of brain injury.
The importance of this milestone lies in the significant unmet medical need for concussion treatments. Currently, there are no FDA-approved pharmacological therapies for mTBI, which affects millions of people annually. ONP-002 aims to address the underlying pathophysiology of concussion, potentially offering a targeted treatment option. The intranasal delivery platform is designed to bypass the blood-brain barrier and deliver the drug directly to the brain, which could enhance efficacy and reduce systemic side effects.
Oragenics is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The company is working on advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.
The Phase IIa trial represents a critical step in the development of ONP-002. The early dosing progress indicates that the trial is proceeding as planned, and the activation of additional sites will likely accelerate enrollment. Positive results from this trial could pave the way for larger Phase 2b studies in the United States and potentially lead to regulatory approval.
For more information, visit oragenics.com.
To view the full press release, visit https://ibn.fm/s2fJa.
